Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypersensitivity to Sugammadex in Healthy Subjects
NCT02028065Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2014
- Primary completion
- Jul 2014
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB) (3 arms), sponsored by Merck & Co. Primary endpoint: Percentage of Participants With Adjudicated Symptoms of Hypersensitivity. Started Jan 2014; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT02028065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028065.